Home Β» Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression

Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression

by Kate Gessner, MD, PhD | Feb 27, 2025 | Articles | 0 Comments